ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/11/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Apellis Pharmaceuticals ( APLS ) reported positive phase 3 results of pegcetacoplan (APL-2) in PNH patients. Pegcetacoplan, the company's C3 inhibitor, managed to beat Alexion Pharmaceuticals' ( ALXN ) eculizumab (Soliris) on the primary endpoint and to show positive trends on multiple secon...

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) rose nearly 41% today after the company reported that its lead drug candidate proved superior to a competitor's therapy on a key clinical metric for individuals with paroxysmal nocturnal hemoglobinuria (PNH). The rare blood disease is characte...

Apellis Pharmaceuticals (NASDAQ: APLS) announced results on Tuesday from its Pegasus late-stage clinical study evaluating experimental drug pegcetacoplan (APL-2) in treating adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The biotech company stated that p...

Apellis Pharmaceuticals (NASDAQ: APLS ) jumps  49%  premarket on robust volume in reaction to positive results from a Phase 3 clinical trial, PEGASUS , evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Apellis Pharmaceutic...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14th, 2019 at 7:30 a.m, PT. A breakout question and answer session will immediately follow the formal presentation. ...

To say that the stock market was unstoppable in 2019 would be quite the understatement. The benchmark S&P 500 and tech-heavy Nasdaq Composite wound up gaining 29% and 35%, respectively, for the year, which for the S&P 500 is about four times its average annual return, inclusive of di...

We have witnessed a number of weak results, attempts for "positive" data misinterpretations and manipulations with TAM in this area which generally make it quite hard to determine real clinical benefit and take time to predict commercial success for the companies involved in the development of...

2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...

Alexion: Investment Thesis Indicative future rates of return from an investment in Alexion ( ALXN ) shares at the current share price level are in the region of 8% to 9% per year, based on analysts' consensus estimates, and provided the P/E multiple remains around current level. But there ...